Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MultiCell Technologies, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: CENTrader who wrote (62)	6/7/2005 4:25:59 PM
From: Shawn Donahue	Respond to of 237

MultiCell Licensee XenoTech Holds Drug Metabolism Symposium Monday June 6, 8:30 am ET [CT, You are very welcome! Yes, it appears that the potential is still promising, IMHO. Take care,Shawn] LINCOLN, R.I.--(BUSINESS WIRE)--June 6, 2005--MultiCell Technologies, Inc. (OTCBB:MCET - News) a leading supplier of immortalized hepatocytes as pharmaceutical candidate optimization tools, announced today that its licensee, XenoTech, LLC, will present MultiCell's unique, functional hepatocytes at a two-day symposium June 6th and 7th. The XenoTech Drug Metabolism Symposium features some of the pharmaceutical industry's most prominent scientists in an intense two-day conference on the various in-vitro challenges of drug discovery and development, including emerging practices, current industry trends and new technologies to support these efforts. The symposium will be held at XenoTech's headquarters in Lenexa, Kansas. Attendees will hear information regarding drug metabolism, enzyme inhibition, in-vitro toxicity, enzyme induction, in-vitro/in-vivo correlations, transporters and regulatory issues in a dynamic forum with comprehensive panel discussions. Dr. Andrew Parkinson, XenoTech founder and CEO, will present "Enzyme Induction and Applications for the Fa2N-4 Immortalized Hepatocytes". MultiCell holds the patents on these Fa2N-4 non-tumorigenic immortalized human hepatocytes and has patented strategies for isolation of adult human liver stem cells. For more information about the Company call 401-333-0610 or see www.multicelltech.com. MultiCell's new laboratories are at 701 George Washington Highway, Lincoln, Rhode Island 02865. Except for the historical information contained herein, this press release contains forward-looking statements, including, without limitation, statements containing the words, "believes," "anticipates," "expects," and words of similar import. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those set forth in the forward looking statements. These risks include, among others, the impact of the reverse stock split on the common stock price and the company's ability to attract institutional ownership and analyst coverage, the risk that the company may not achieve profitability, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report on form 10-KSB for the fiscal year ended November 30, 2004, and its Quarterly Reports on Form 10-QSB and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. Contact: MultiCell Technologies, Inc. Jerry Newmin, 401-333-0610 or CEOcast, Inc. for MultiCell Ed Lewis, 212-732-4300 Source: MultiCell Technologies, Inc. biz.yahoo.com